Drug intelligence / Profile preview

ILB-2110

Development stage: Preclinical
Lead developer: Innolake Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ILB-2110 is a preclinical-stage monoclonal antibody developed by Innolake Biopharm for the treatment of autoimmune diseases. It targets the Programmed Cell Death Protein 1 (PD-1) receptor, acting as an agonist to suppress overactive T-cell responses and restore immune homeostasis. This mechanism contrasts with PD-1 inhibitors used in oncology, which aim to activate the immune system against cancer cells. ILB-2110 is currently in the preclinical phase of development and represents a targeted approach to managing immune-mediated inflammatory conditions by leveraging natural immune checkpoint pathways.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ILB-2110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-2110.

Explore the full profile